Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study

BACKGROUND: Vedolizumab has become a standard treatment for the inflammatory bowel diseases ulcerative colitis (UC) and Crohn’s disease (CD). However, there is an ongoing debate on the ideal individual treatment algorithms and means to predict treatment response are not routinely established. AIMS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Mühl, Laura, Becker, Emily, Müller, Tanja M., Atreya, Raja, Atreya, Imke, Neurath, Markus F., Zundler, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821503/
https://www.ncbi.nlm.nih.gov/pubmed/33482730
http://dx.doi.org/10.1186/s12876-021-01604-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821503/
https://www.ncbi.nlm.nih.gov/pubmed/33482730
http://dx.doi.org/10.1186/s12876-021-01604-z

Ejemplares similares